LifeCycle Pharma Announces Positive Topline Results From Phase II Clinical Study Of LCP-Tacro Once Daily In Stable Liver Transplant Patients

LifeCycle Pharma A/S (OMX:LCP) announced positive top-line results from a completed Phase II clinical study of LCP-Tacro tablets in stable liver transplant patients which are in line with earlier data announced for stable kidney transplant patients.

More: continued here

Filed under: Liver Disease / Hepatitis on July 16th, 2008